Overview
- Trulieve began trading on the New York Stock Exchange under the ticker TRLV on Wednesday, June 10, 2026, after obtaining NYSE approval.
- The company separated its medical business from adult-use operations by spinning off mixed-use assets and selling a minority stake so its consolidated books reflect a medical-only operator.
- Trulieve’s medical-only consolidation includes about 206 dispensaries and roughly 3.5 million square feet of DEA-registered production capacity, figures the company provided during the uplisting process.
- The April rescheduling to Schedule III cleared a route for DEA registration and could reduce the Section 280E tax burden that previously barred ordinary expense deductions for Schedule I operators, improving medical operators’ federal tax profiles if the change holds.
- Investors and rivals will watch near-term trading and an upcoming DEA hearing starting June 29, 2026, on whether recreational cannabis should also be rescheduled because that decision could prompt more uplistings or further corporate restructurings.